Alumis Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.7 million (-37.7% year over year) and diluted EPS of -$1.11. It usually reports 9–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 9–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
2
-37.7%
|
-142
-339.7%
|
-1.11
-244.2%
|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2
-90.0%
|
-93
+6.0%
|
-0.74
+59.3%
|
|
Jan 9, 2026
9 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
2
|
-93
+1.9%
|
-0.89
+49.2%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2
|
-111
-18.9%
|
-1.06
+38.7%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
3
|
59
+205.0%
|
0.77
+103.3%
|
|
May 14, 2025
44 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
17
|
-99
|
-1.82
|
|
Feb 6, 2025
37 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-95
|
-1.75
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-93
|
-1.73
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALMS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1847367
- Former names
- FL2021-001, Inc. (until Mar 19, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.